title: Antibacterial resistance leadership group: open for business.
abstract: Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.
authors.affiliation: Department of Medicine, University of California, San Francisco.
authors.forename: Henry F
authors.initials: HF
authors.lastname: Chambers
authors.forename: John G
authors.initials: JG
authors.lastname: Bartlett
authors.forename: Robert A
authors.initials: RA
authors.lastname: Bonomo
authors.forename: Christine
authors.initials: C
authors.lastname: Chiou
authors.forename: Sara E
authors.initials: SE
authors.lastname: Cosgrove
authors.forename: Heather R
authors.initials: HR
authors.lastname: Cross
authors.forename: Robert S
authors.initials: RS
authors.lastname: Daum
authors.forename: Michele
authors.initials: M
authors.lastname: Downing
authors.forename: Scott R
authors.initials: SR
authors.lastname: Evans
authors.forename: Jane
authors.initials: J
authors.lastname: Knisely
authors.forename: Barry N
authors.initials: BN
authors.lastname: Kreiswirth
authors.forename: Ebbing
authors.initials: E
authors.lastname: Lautenbach
authors.forename: Brenda S
authors.initials: BS
authors.lastname: Mickley
authors.forename: Robin
authors.initials: R
authors.lastname: Patel
authors.forename: Melinda M
authors.initials: MM
authors.lastname: Pettigrew
authors.forename: Keith A
authors.initials: KA
authors.lastname: Rodvold
authors.forename: Brad
authors.initials: B
authors.lastname: Spellberg
authors.forename: Vance G
authors.initials: VG
authors.lastname: Fowler
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D035843:Biomedical Research / Q000639:trends*; D002202:Capital Financing; D024881:Drug Resistance, Bacterial; D004363:Drug Utilization / Q000592:standards*; D006801:Humans; D007857:Leadership; D054579:National Institute of Allergy and Infectious Diseases (U.S.); D014481:United States
chemical_list: D000900:Anti-Bacterial Agents
keywords: ARLG; Leadership Group; antibacterial resistance; clinical research; clinical trials